A1G
0.527
67.3%
CAN
0.009
-18.2%
ERA
0.003
50%
HWK
0.027
-18.2%
RBRDA
0.015
36.4%
CYQ
0.005
-16.7%
EDU
0.81
33.9%
EMT
0.005
-16.7%
FBR
0.004
33.3%
IPT
0.005
-16.7%
M4M
0.008
33.3%
4DS
0.011
-15.4%
BOC
0.79
29.5%
IBX
0.022
-15.4%
AYT
0.005
25%
EE1
0.006
-14.3%
GR8
0.2
25%
G88
0.006
-14.3%
PGY
0.005
25%
OVT
0.006
-14.3%
RLG
0.005
25%
HYD
0.013
-13.3%
TMX
0.005
25%
VML
0.195
-13.3%
WLD
0.016
23.1%
FAL
0.55
-12.7%
YUG
0.064
20.8%
TNC
0.55
-12.7%
APC
0.012
20%
FAU
0.007
-12.5%
PIQ
0.48
20%
FRX
0.014
-12.5%
VRC
0.006
20%
MNB
0.03
-11.8%
RGL
0.007
16.7%
MVL
0.015
-11.8%
8CO
0.029
16%
ORP
0.045
-11.8%
LPM
0.155
14.8%
T92
0.053
-11.7%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AGN on track for Phase 2 trials during CY24

Argenica Therapeutics (ASX:AGN) has completed the manufacturing of the ARG-007 drug required for Phase 2 clinical trials. The finalised, sterile drug product manufacturing will be completed by the end of the year keeping the Argenica on track for first patient dosing during Q1 CY24 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf $AGN #Phase2 #ClinicalTrials #shorts